Amarin picks up Pawn Stars host to pitch its struggling fish-oil pill, Vascepa

The market for Omega 3-based prescription drugs was just a one-drug wonder. GlaxoSmithKline's ($GSK) Lovaza, designed to lower triglyceride levels in patients with cardiovascular disease, was all by its lonesome there, with £584 million, or about $1 billion, in 2013 sales.

That was just a few months ago. But now, there are not only two more fish-oil-based brands--Amarin's ($AMRN) Vascepa and AstraZeneca's ($AZN) Epanova--but a generic version of Lovaza, too. And all four are looking for their share of a market that is still more potential than actual.

So what do the new kids on the block do? Sign up a celebrity pitchman, if you're Amarin, which is still scrambling for a real foothold. As Medical Marketing & Media reports, the company has tied up with the host of the cable TV show Pawn Stars, Rick Harrison, in an integrated campaign run by Makovsky as agency-of-record. The campaign follows Amarin's co-promotional deal with Kowa Pharmaceuticals, which created a sales force of 380 reps to take advantage of any DTC buzz.

Vascepa is the real deal, Harrison suggests in a video on the site LowerMyTrigs.com. Just as he focuses on value and authenticity when buying merch for his shop, he's turning to the prescription pill--not an over-the-counter supplement--to lower his triglycerides. Harrison also touts something that Amarin considers key to Vascepa's profile: It doesn't tend to raise "bad" LDL cholesterol as Lovaza can, the company says.

Rick Harrison

AstraZeneca, meanwhile, is telling a fish story in its unbranded digital effort. As MM&M reports, AZ has posted three videos in its "Take It from a Fish" series, putting words about healthy eating habits into a few talking fishes' mouths. The awareness campaign is now on YouTube, and it will fan out across various digital channels, including social media.

As for Teva Pharmaceutical Industries' ($TEVA) generic version of Lovaza, it won approval in April and launched soon thereafter. Its marketing hook--price--doesn't require DTC advertising.

The original brand is hanging in there, despite the earlier-than-expected generic competition. Glaxo did take a charge against 2013 earnings for "partial impairment" of the Lovaza brand, anticipating Teva's generic launch. Its first-quarter sales didn't match up to 2013 levels, but still amounted to about $175 million.

- read the MM&M story

Suggested Articles

​​​​​​​Baseball and allergy season are in full swing, and Houston Astros pitcher Justin Verlander knows both. He stars in GSK's new seasonal push.

PhRMA’s latest round of drug-cost ads defends a drugmaker favorite—the copay coupon—against new payer programs designed to thwart it.

Researchers plan to tackle issues related to accelerated approval, risk comprehension for new drugs, scientific versus promotional claims and TV ads.